You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Journal club
Gefitinib as first-line treatment in advanced NSCLC with mutated EGFR
  1. Salma Naheed
  1. Correspondence to Salma Naheed, Royal London Hospital, Whitechapel Road, Whitechapel, London, E1 8PR, UK; salma.naheed{at}gmail.com

https://doi.org/10.1136/thx.2010.151308

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths. Standard cytotoxic chemotherapy has a response rate of only 20–35% and median survival among patients with advanced NSCLC is between 10 and 12 months. Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is used in patients with NSCLC with sensitive mutations of EGFR, and …

    View Full Text